Icatibanto piramal 30 mg solucion inyectable en jeringa precargada efg
How to use Icatibanto piramal 30 mg solucion inyectable en jeringa precargada efg
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Label: information for the user
Icatibant Piramal 30 mg injectable solution in pre-filled syringe EFG
Read this label carefully before starting to use this medication, as it contains important information for you.
- Keep this label, as you may need to read it again.
- If you have any questions, consult your doctor or pharmacist.
- This medication has been prescribed only to you and should not be given to others even if they have the same symptoms as you, as it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this label. See section 4.
1. What is Icatibanto Piramal and what is it used for
Icatibanto Piramal contains the active ingredient icatibanto.
Icatibanto is used for the treatment of symptoms of hereditary angioedema (HAE) in adults, adolescents, and children over 2 years old.
In HAE, concentrations of a substance present in the blood called bradykinin increase, which produces symptoms such as swelling, pain, nausea, and diarrhea.
Icatibanto blocks the activity of bradykinin and, therefore, slows the progression of symptoms.
2. What you need to know before starting to use Icatibant Piramal
No use Icatibanto Piramal
- If you are allergic to icatibanto or any of the other components of this medication (listed in section 6).
Warnings and Precautions
Consult your doctor before starting to use Icatibanto.
- If you suffer from angina pectoris (decreased blood flow to the heart).
- If you have recently had a stroke.
Some of the side effects related to Icatibanto are similar to the symptoms of your own disease. Consult your doctor immediately if you notice that the symptoms of the crisis worsen after you are administered this medication.
Additionally:
- You or your caregiver must learn the technique of subcutaneous injection (under the skin) before self-administering or having your caregiver administer this medication to you.
- Immediately after self-administering Icatibanto or having your caregiver administer it to you while experiencing a laryngeal crisis (obstruction of the upper airway), you must seek medical attention at a medical institution.
- If your symptoms do not resolve after an injection of Icatibanto self-administered or administered by your caregiver, you must consult your doctor about the administration of additional injections of this medication. In adult patients, up to 2 additional injections may be administered within a 24-hour period.
Children and Adolescents
Icatibanto is not recommended for use in children under 2 years of age or weighing less than 12 kg because it has not been studied in these patients.
Other Medications and Icatibanto Piramal
Inform your doctor if you are taking, have recently taken, or may need to take any other medication.
No interactions of Icatibanto with other medications are known. If you are taking any medication that is an angiotensin-converting enzyme inhibitor (ACEI) (for example: captopril, enalapril, ramipril, quinapril, lisinopril) to reduce blood pressure or for any other reason, inform your doctor before receiving this medication.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or intend to become pregnant, consult your doctor before starting to use Icatibanto.
If you are breastfeeding, do not breastfeed your child for 12 hours after the last administration of Icatibanto.
Driving and Operating Machines
Do not drive or operate machines if you feel tired or dizzy as a result of the AEH crisis or after using Icatibanto.
Icatibanto Piramal contains sodium
This medication contains less than 23 milligrams (1 mmol) of sodium per injectable solution, making it essentially "sodium-free".
3. How to use Icatibant Piramal
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor again.
If you have never received Icatibanto before, the first dose must always be injected by medical or nursing staff. Your doctor will discharge you when they consider it safe for you to go home. After analyzing it with your doctor or nurse, and after learning the technique for subcutaneous injections (under the skin), you or the person who takes care of you can administer Icatibanto if you have an AEH crisis. It is essential to inject Icatibanto subcutaneously (under the skin) as soon as you notice a crisis of angioedema. Healthcare personnel will teach you and the person who takes care of you how to inject this medication safely, following the prospectus instructions.
When and how often should you use Icatibanto Piramal?
Your doctor has determined the exact dose of Icatibanto and will tell you how often to use it.
Adults
- The recommended dose of Icatibanto is one injection (3 ml, 30 mg) administered subcutaneously (under the skin) as soon as you notice the angioedema crisis (for example, with increased skin swelling, especially on the face and neck, or increased abdominal pain).
- If you do not notice an improvement in symptoms, after six hours, you should consult a doctor about the administration of additional Icatibanto injections. In adults, up to two additional injections can be administered within 24 hours.
- You should not receive more than 3 injections in a 24-hour period and if you need more than 8 injections in a month, you should consult a doctor.
Children and adolescents from 2 to 17 years old
- The recommended dose of Icatibanto is one injection of 1 ml up to a maximum of 3 ml, depending on body weight, injected subcutaneously (under the skin) as soon as symptoms of an angioedema crisis appear (for example, increased skin swelling, especially on the face and neck, or increased abdominal pain).
- See the usage instructions section to see the dose you should inject.
- If you are unsure about the dose you should inject, consult your doctor, pharmacist, or nurse.
- If your symptoms worsen or do not improve, you should seek immediate medical attention.
How should Icatibanto Piramal be administered?
This medication is administered by subcutaneous injection (under the skin). Each syringe should be used only once.
Icatibanto is injected with a short needle into the fatty tissue located under the skin of the abdomen (stomach).
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
The following step-by-step instructions are intended for:
- self-administration (adults)
- administration by a caregiver or healthcare professional to adults, adolescents, or children over 2 years old (who weigh at least 12 kg).
The instructions include the following main steps:
1)General information
2a)Preparation of the syringe for children and adolescents (2-17 years) who weigh 65 kg or less
2b)Preparation of the syringe and needle for injection (all patients)
- Preparation of the injection site
- Injection of the solution
- Disposal of injection materials
Step-by-step instructions for injection
- General information
- Clean the work surface area to be used before starting the process.
- Wash your hands with water and soap
- Extract the pre-loaded syringe from the container.
- Loosen and remove the cap from the end of the pre-loaded syringe.
- Leave the pre-loaded syringe once the cap has been loosened.
2a) Preparation of the syringe for children and adolescents (2-17 years) who weigh 65 kg or less: |
Important information for healthcare professionals and caregivers: When the dose is less than 30 mg (3 ml), the following equipment is needed to extract the correct dose (see information below):
The required injection volume in ml should be prepared in a 3 ml graduated syringe that is empty (see table below). |
Table 1: Dosage schedule for children and adolescents Patients who weighmore than 65 kgwill use the entire contents of the pre-loaded syringe (3 ml). If you are unsure about the volume of solution to extract, consult your doctor, pharmacist, or nurse
Avoid touching the connector ends and needle tips to prevent contamination
Transfer the icatibanto solution to the graduated syringe: 1) To initiate the transfer of the icatibanto solution, push the plunger of the pre-loaded syringe (on the left side of the image below). |
If there is air in the graduated syringe:
|
|
2b) Preparation of the syringe and needle for injection: All patients (adults, adolescents, and children) |
|
3) Preparation of the injection site |
|
4) Injection of the solution |
|
|
5) Disposal of injection materials |
|
4. Possible Adverse Effects
Like all medications, this medication may produce adverse effects, although not everyone will experience them. Almost all patients who receive Icatibant notice a reaction at the injection site (such as skin irritation, inflammation, pain, itching, skin redness, and burning). These effects are usually mild and improve without the need for additional treatment.
Very common (may affect more than 1 in 10 people):
Additional reactions at the injection site (sensation of pressure, bruising, decreased sensitivity and/or numbness, increased skin rash with itching and heat).
Common (may affect up to 1 in 10 people):
Nausea
Headache
Dizziness
Fever
Itching
Rash
Redness of the skin
Abnormal liver function tests
Unknown frequency (cannot be estimated from available data):
Hives (urticaria)
Inform your doctor immediately if you observe that the symptoms of the attack worsen after receiving this medication.
If you experience adverse effects, consult your doctor, even if they are adverse effects that do not appear in this prospectus.
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is possible adverse effects that do not appear in this prospectus.You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
5. Conservation of Icatibanto Piramal
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C. Do not freeze.
Do not use this medication if you observe that the syringe or needle container is damaged or if you observe visible signs of deterioration; for example, if the solution is cloudy, if it contains floating particles or if the solution color has changed.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
6. Contents of the packaging and additional information
Icatibanto Piramal Composition
- The active ingredient is icatibanto.Cada jeringa precargada contiene 30 miligramos de icatibanto (como acetato). Cada ml de la solución contiene 10 mg de icatibanto.
- The other components are: sodium chloride, glacial acetic acid (buffering agent), sodium hydroxide (to adjust pH) and water for injection (see section 2).
Product Appearance and Packaging Contents
Icatibanto Piramal is presented as a transparent and colorless injectable solution in a 3 ml pre-filled syringe.
The packaging contains a hypodermic needle.
Icatibanto is available in a single pre-filled syringe with a needle or in a multiple packaging of three pre-filled syringes with three needles.
Only some packaging sizes may be commercially available.
Marketing Authorization Holder and Responsible Manufacturer
Marketing Authorization Holder
Piramal Critical Care B.V.
Rouboslaan 32 (ground floor),
Voorschoten 2252 TR
Netherlands
Responsible Manufacturer
Laboratorios Eurofins PROXY
(B.V.)
Archimedesweg 25
2333 CM Leiden
Holland
or
Pharmadox Healthcare Ltd.
KW20A Kordin Industripark
Paola PLA 3000
Malta
For more information about this medication, please contact
the local representative of the marketing authorization holder:
Euromed Pharma Spain, S.L.C/Eduard Maristany, 430-432
08918 Badalona
Barcelona - Spain
Phone: + 34 932 684 208
Fax: + 34 933 150 469
This medication is authorized in the European Economic Area (EEA) member states with the following names:
Denmark: Icatibant Piramal
Germany: Icatibant Piramal 30 mg Injektionslösung in einer Fertigspritze
Spain: Icatibanto Piramal 30 mg solución inyectable en jeringa precargada EFG
France: Icatibant Piramal 30 mg solución inyectable, seringue pré-remplie
Italy: Icatibant Piramal
Last review date of thisleaflet: 09/2021
The detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to Icatibanto piramal 30 mg solucion inyectable en jeringa precargada efgDosage form: INJECTABLE, 30 mgActive substance: icatibantManufacturer: Takeda Pharmaceuticals International Ag Ireland BranchPrescription requiredDosage form: INJECTABLE, 30 mgActive substance: icatibantManufacturer: Accord Healthcare S.L.U.Prescription requiredDosage form: INJECTABLE, 30 mgActive substance: icatibantManufacturer: Laboratoire AguettantPrescription required
Online doctors for Icatibanto piramal 30 mg solucion inyectable en jeringa precargada efg
Discuss questions about Icatibanto piramal 30 mg solucion inyectable en jeringa precargada efg, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
